与HER2-low TNBC相比,HER2-negative TNBC具有更活跃的免疫微环境特征 CD8+效应T细胞、CD4+增殖T细胞和幼稚T细胞在HER2-negative组中似乎更常见。单细胞(T细胞)受体测序(scTCR-seq)结果显示,HER2-negative组具有更丰富的TCR多样性。与HER2-low TNBC相比,HER2-negative TNBC表现出更高的巨噬细胞浸润(主要是M2表型)。GE...
Tsuji Y, Makiyama A, Nakashima Y, Ota M, Kimura Y, Yoshizumi T. Genomic characterization between HER2-positive and negative gastric cancer patients in a prospective trial. Cancer Med. 2023 Jun 16. doi: 10.1002/cam4.6269. Epub ahead of print. ...
与HER2-low TNBC相比,HER2-negative TNBC具有更活跃的免疫微环境特征 CD8+效应T细胞、CD4+增殖T细胞和幼稚T细胞在HER2-negative组中似乎更常见。单细胞(T细胞)受体测序(scTCR-seq)结果显示,HER2-negative组具有更丰富的TCR多样性。与HER2-low T...
[11]Aditya Bardia, Komal Jhaveri, Seock-Ah Im, et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previouslytreated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised Phase 3 TROPION-Breast01 trial...
[7].Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol 2017;28:2420–8.* 本文由阿斯利康提供支持，仅供医疗专业人士参考 审批编号：CN-106964 有效期至：2023-12-6 *此...
[4] Rossi V, Sarotto I, Maggiorotto F et al (2012) Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. Oncologist 17:1418–1425. [5] Eggemann H, Ignatov T, Burger E et al (2015) Moderate HER...
[1]Gion M, Trapani D, Cortés A, et al. Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era. Am Soc Clin Oncol Educ Book. 2022;42:1-11. [2]商久妍,贾珂琪,郭启涛,等.乳腺癌HER-2表达异质性的研究进展及临床意义[J].临床与实验病理学杂志,2023,39(03):339...
[18]Nitz U, Gluz O, Graeser M, et al. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 ...
Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...
1、GS4-10 Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial. 2021 SABCS 2、Yi Z, Rong G, Guan Y, et al. Molecular landscape and efficacy of HER...